Cochrane · systematic review · CD006250
Bisphosphonates for advanced prostate cancer
Macherey, S, Monsef, I, Jahn, F, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
7
No studies
1
Included studies
NR
No studies 1 · 12.5%Ungraded 0 · 0%Very low 1 · 12.5%Low 1 · 12.5%Moderate 5 · 62.5%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Bisphosphonates compared to placebo/no treatment for advanced prostate cancer
Population: men with advanced prostate cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants with pain response Bisphosphonates vs placebo/no treatment | RR 1.15 [0.93, 1.43] | 3 studies · 876 participants | Low Downgraded: risk of bias |
Skeletal‐related events: any, composite outcome Bisphosphonates vs placebo/no treatment | RR 0.87 [0.81, 0.94] | 9 studies · 3153 participants | Moderate Downgraded: risk of bias, imprecision |
Mortality Bisphosphonates vs placebo/no treatment | RR 0.97 [0.91, 1.04] | 9 studies · 2450 participants | Moderate Downgraded: risk of bias, imprecision |
Quality of life Bisphosphonates vs placebo/no treatment | no estimate extracted | NR | No studies |
Adverse events: nausea Bisphosphonates vs placebo/no treatment | RR 1.19 [1, 1.41] | 9 studies · 3008 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse events: renal Bisphosphonates vs placebo/no treatment | RR 1.65 [1.11, 2.46] | 7 studies · 1794 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse events: osteonecrosis of the jaw Bisphosphonates vs placebo/no treatment | RR 1.92 [0.75, 4.9] | 5 studies · 1626 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants with disease progression Bisphosphonates vs placebo/no treatment | RR 0.95 [0.9, 0.99] | 7 studies · 2115 participants | Moderate Downgraded: risk of bias, imprecision |